Today the FDA said the drug, desmopressin, should no longer be used to treat bed-wetting in both children and adults. Reports of seizures and even death have been associated with the drug. Several different companies sell Desmopressin in several different combinations from oral to injectable. Sanofi-Aventis sell several versions under the name DDAVP.
The drug limits the amount of water that’s eliminated in the urine and is used to prevent and control excessive thirst, urination and dehydration caused by injury, surgery and certain medical conditions including a form of diabetes, Dow Jones Newswires reports.
The FDA says they have received reports of 61 seizures, of which 36 were associated with the nasal spray form of the drug. Two deaths have also been reported. It is not clear if the drug caused the reported deaths but both patients did experience seizures and hyponatremia, a condition characterized by extremely low levels of sodium in the body.
The tablet form of desmopressin can still be used to treat bed-wetting but should still be closely monitored.
For more information on this subject, please refer to the section on Drugs, Medical Devices and Implants.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.